SCWorx Corp.: directors' dealings · United States · SEC (Form 4)

About SCWorx Corp.

SCWorx Corp. (ticker: WORX) is a United States-based company listed on the Nasdaq market, and it operates in the healthcare technology segment. The company provides data-content and data-services solutions focused on repairing, normalizing, and improving interoperability across healthcare information systems. Its core offering is a software-as-a-service platform built around an advanced attributed virtualized item data warehouse, which SCWorx says is enhanced with machine learning and artificial intelligence to support healthcare providers with better data quality, benchmarking, reporting, cost control, and operational efficiency. ([nasdaq.com](https://www.nasdaq.com/press-release/scworx-announces-compliance-nasdaqs-periodic-reporting-listing-standard-2024-11-20)) From a corporate history perspective, SCWorx is a relatively small, development-stage public company rather than a mature scaled software platform. Its SEC filings indicate an ongoing effort to broaden the product set, attract new customers, and improve monetization of its healthcare data capabilities. The company’s business address is in New York, reflecting a U.S. operating footprint and a headquarters presence in one of the key financial and commercial centers in the country. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1674227/000121390024028666/0001213900-24-028666-index.html?utm_source=openai)) SCWorx competes in a niche but strategically important part of healthcare IT: the management, accuracy, and interoperability of item and clinical data used by hospitals and other providers. Its competitive position is that of a specialized small-cap vendor, with a value proposition centered on cost savings, process automation, and improved reporting accuracy rather than broad enterprise healthcare software coverage. In that sense, it is more of a focused infrastructure provider than a generalist healthcare technology platform. ([nasdaq.com](https://www.nasdaq.com/press-release/scworx-announces-compliance-nasdaqs-periodic-reporting-listing-standard-2024-11-20)) Its principal business lines are concentrated on healthcare data services and SaaS-based software tools, not on pharmaceuticals, medical devices, or direct clinical services. This focus makes the company’s commercial story relatively clear, but also leaves it exposed to customer concentration, contract timing, and the pace of adoption inside hospital systems. The company’s own disclosures show that management continues to look for new products and additional revenue sources to support growth. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1674227/000121390026037303/ea0281680-10k_scworx.htm)) Recent developments have been notable for investors. The latest annual filing reported a revenue decline in 2025 and disclosed senior secured convertible notes backed by substantially all company assets, highlighting a leveraged and potentially dilutive capital structure. SCWorx also disclosed Nasdaq minimum bid price compliance issues, with an extension granted until April 6, 2026 and the potential need for a reverse stock split if the share price does not recover. Earlier Nasdaq communications confirmed that periodic reporting deficiencies had been cured and that the stock continued trading on Nasdaq, but the more recent bid-price notice underscores the company’s elevated micro-cap risk profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1674227/000121390026037303/ea0281680-10k_scworx.htm))